An intravitreal device providing sustained release of cyclosporine and dexamethasone

Abstract

We conclude that the device maintains potentially therapeutic levels of both cyclosporine and dexamethasone in the vitreous. Reversible electroretinographic abnormalities are attributable to cyclosporine. A sustained-release device containing cyclosporine and dexamethasone may be useful for reducing inflammation in diseases such as proliferative vitreoretinopathy and uveitis.

Therapeutic and Toxicological Evaluations of Cyclosporine A Microspheres as a Treatment Vehicle for Uveitis in Rabbits

“…The toxicity of formulation 3 possibly resulted from CsA itself, judging from the comparison of formulation 3 (CsA-PLGA-MS with PF68) with PLGA-MS with or without PF68, and this is consistent with the previous reports about the CsA device. 13 The same test also demonstrated that no retinal toxicity of PF68 was observed. Additionally, PF68 was approved by the U.S. Food and Drug Administration for use in humans, even for intravenous injection.…”

Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences

“…Proposed treatments should guarantee efficient levels of therapeutic agents at the right target during this time. There are a few older reports that propose sustained delivery systems for treating PVR (Enyedi et al, 1996;Yang et al, 1998;Zhou et al, 1998). Currently we have gained more clinical experience with drug delivery systems, and there are new possibilities that should be explored.…”

Study of Ocular Transport of Drugs Released from an Intravitreal Implant Using Magnetic Resonance Imaging

“…24,36 To overcome the limitations of delivering drugs to the eye by topical administration, systemic injection, and intravitreal injection, interest has increased in the use of sustained release delivery methods. 2,6,11,31,42 Well known is the intravitreal ganciclovir implant (Vitrasert, Bausch & Lomb) for treating cytomegalovirus retinitis in AIDS. 9 The distribution of injected materials in the vitreous has been studied theoretically and experimentally 13,34,41 and the movement of drugs released from an implant in the vitreous has been studied theoretically.…”